Yahoo · Nov 13, 2025
Provectus: Q3 Earnings Snapshot
KNOXVILLE, Tenn. AP) — Provectus Biopharmaceuticals Inc. PVCT) on Thursday reported a loss of $1.3 million in its third quarter.
PV
OTC · PVCT
Provectus Biopharmaceuticals, Inc.
Healthcare · Biotechnology
$0.05
Down-$0.00 (-7.83%)
Updated Aug 13, 2026, 10:03 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 27.23M
- P/E ratio
- -4.06
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 0
- Avg. volume
- 239.5K
Price performance
PVCT price history
1M range · 0 trading sessions · Daily adjusted prices
PVCT does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest PVCT news
The latest Smart Investors Daily articles mentioning PVCT.
Stock researchCompany · Overview
PVCT research
Overview
Company profile and research snapshot.
Company profile
PROVECTUS BIOPHARMS
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
globenewswire.com · Oct 9, 2025
Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy
KNOXVILLE, Tenn., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of independent preclinical research by Aru Narendran, MD, PhD and colleagues at the University of Calgary's Cumming School of Medicine in Human Vaccines & Immunotherapeutics.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
